Lore Gruenbaum, PhD, discusses the FDA approval of brexu-cel for mantle cell lymphoma and its significance for the treatment paradigm.
Back
Dr Gruenbaum on the Significance of the FDA Approval of Brexu-cel for MCL
Dr Gruenbaum on the Significance of the FDA Approval of Brexu-cel for MCL
Episodes
All
All
Lore Gruenbaum, PhD, discusses developments in mantle cell lymphoma management that she has her eye on and critical unmet needs in the field.
Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
The OncFive: Top Oncology Articles for the Week of 8/2
4
Sonrotoclax Is Active in Chinese R/R MCL Cohort of the BGB-11417-201 Trial
5